Shang Jyh Kao1, Chiao Hsu Ke2, Chen Si Lin2 and Yu Shan Wang2,3*
This comprehensive review delves into the DR-70 biomarker's role in canine cancer detection, its potential in prognosis, and monitoring treatment responses. Initially identified as a promising diagnostic tool, DR-70 has demonstrated significant accuracy and sensitivity in identifying various canine tumors. Beyond detection, recent studies have begun exploring its capabilities as a prognostic tool, examining its correlation with cancer stages, types, and expected outcomes. These investigations suggest that DR-70 levels may vary with different cancer types and stages, potentially indicating disease progression and treatment efficacy. Additionally, the review compares DR-70's effectiveness with other biomarkers like C-reactive protein, circulating tumor DNA, and another promising biomarker, nucleosome, discussing the benefits of a multi-biomarker approach for a more comprehensive understanding of canine cancers. Despite the promise, challenges in specificity, sensitivity, and the influence of concurrent diseases pose limitations to DR-70's clinical utility. The review emphasizes the need for further research, larger cohorts, and advanced technological approaches to enhance the biomarker's reliability and application. It concludes by highlighting the promising future of DR-70 in veterinary oncology, where it could significantly improve prognosis, tailor treatment strategies, and ultimately enhance the management and outcomes of oncological conditions in dogs. The collective efforts in research and technological advancements are crucial in realizing the full potential of DR-70 as a multifaceted tool in the fight against canine cancer.
English 
Spanish 
Chinese 
Russian 
French 
Japanese 
Portuguese 
Hindi